Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regent Pacific GroupRPGLF 13 EV-to-EBITDA is -8.69 as of Jul. 18, 2026. GuruFocus rates RPGLF with a GF Score™ of 13/100. The stock has 7 warning signs investors should review. Among 741 Drug Manufacturers companies, Regent Pacific Group ranks worse than 134952.63% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Regent Pacific Group's enterprise value is $37.65 Mil.
Regent Pacific Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.33 Mil. Therefore, Regent Pacific Group's EV-to-EBITDA for today is -8.69.
The historical rank and industry rank for Regent Pacific Group's EV-to-EBITDA or its related term are showing as below:
RPGLF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.09 Med: -4.27 Max: 4.84
Current: -8.81
During the past 13 years, the highest EV-to-EBITDA of Regent Pacific Group was 4.84. The lowest was -24.09. And the median was -4.27.
RPGLF's EV-to-EBITDA is ranked worse than 100% of 741
companies
in the Drug Manufacturers industry
Industry Median: 13.03
vs RPGLF: -8.81
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Regent Pacific Group (OTCPK:RPGLF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Regent Pacific Group's PE Ratio (TTM) for today is calculated as:
Regent Pacific Group's share price for today is $0.0059.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regent Pacific Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.018.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Regent Pacific Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Regent Pacific Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regent Pacific Group EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regent Pacific Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Regent Pacific Group's EV-to-EBITDA falls into.
Regent Pacific Group's current Enterprise Value is $37.65 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regent Pacific Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regent Pacific Group (RPGLF) has a EV-to-EBITDA of -8.69 as of Jul. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Regent Pacific Group. According to the industry distribution chart, Regent Pacific Group ranks #999999 out of 741 companies in the Drug Manufacturers industry.
Is Regent Pacific Group's EV-to-EBITDA too high?
Regent Pacific Group's current EV-to-EBITDA is -8.69. Based on the distribution chart, Regent Pacific Group ranks #999999 out of 741 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Regent Pacific Group has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Regent Pacific Group's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Regent Pacific Group ranks #999999 out of 741 companies for EV-to-EBITDA. This places Regent Pacific Group in the lower half of its industry. The industry median EV-to-EBITDA is 13.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Regent Pacific Group. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regent Pacific Group's current EV-to-EBITDA is -8.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regent Pacific Group stock overvalued right now?
Regent Pacific Group (RPGLF) has a current EV-to-EBITDA of -8.69. The current EV-to-EBITDA is -8.69. Regent Pacific Group's overall GF Score™ is 13/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Regent Pacific Group (RPGLF), the current EV-to-EBITDA is -8.69 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Geographically, the Europe; U.S.; and Asia Pacific. It derives maximum revenue from Europe.
13GF Score
Get the complete analysis for RPGLF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPGLF has been successfully added to your 
